Importantly, our study highlights the prognostic power of molecular markers now integral to glioma classification.[15] We observed that IDH1/2-mutant gliomas had markedly prolonged survival compared to IDH-wildtype tumors. The gene discussed is IDH1; the disease is central nervous system cancer.